A researcher in the College of Pharmacy, University of Karbala participated in the annual international conference of coagulation diseases and blood clotting in Berlin.

The researcher reviewed the incidence of adverse events to the patients with anticoagulant (enoxaparin) and the relation to the BMI.

The researcher also reviewed using low molecular weight heparin enoxaparin, serious potential side effects, methods of determining the therapeutic dose of heparin, risk of increasing dose according to the weight of the patient with overweight and obese.

The researcher aimed at evaluating the adverse effects in patients with acute stroke which are treated with the therapeutic dose of enoxaparin and its relation with BMI.

The researcher said that the study is conducted on 181 patients (98 males and 83 females) with acute thromboembolism (acute venous thromboembolism, acute coronary thromboembolism and acute coronary syndrome), were divided in 3 groups according to their BMI, the first was on normal weight, the second was on weight gain and the thirds was on obesity via monitoring and detecting any adverse effects during treatment with low molecular weight heparin therapy.

It is worth mentioning that the study concluded that bleeding was the most common negative by (8.3%), platelet deficiency by (2.6%), fever by (1.1%) and the hemorrhage and other adverse effects were stable.